z-logo
open-access-imgOpen Access
Loperamide cardiotoxicity: “A Brief Review”
Author(s) -
Akel Tamer,
Bekheit Soad
Publication year - 2018
Publication title -
annals of noninvasive electrocardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.494
H-Index - 48
eISSN - 1542-474X
pISSN - 1082-720X
DOI - 10.1111/anec.12505
Subject(s) - medicine , loperamide , euphoriant , pharmacology , agonist , hypoactivity , opioid , anesthesia , myenteric plexus , intensive care medicine , receptor , psychiatry , diarrhea , immunohistochemistry
Loperamide is a popular antidiarrheal medication that has been used for many years. It is currently gaining more attention among healthcare professionals due to its increasing potential for side effects. At present, it is considered safe enough to be sold over the counter. In contrast with other opioid agonists, loperamide is a peripherally acting μ‐receptor agonist exerting its effects mainly on the myenteric plexus of the gastrointestinal longitudinal muscle layer. It decreases peristalsis and fluid secretion resulting in longer gastrointestinal transit time. The bioavailability of the drug is extremely low. Moreover, it is actively excluded from the central nervous system; hence, it lacks the central effects of euphoria and analgesia at the recommended dosages. Loperamide abuse has been steadily increasing in the United States. Abusers typically ingest high doses in desire to achieve a satisfactory central nervous system drug penetration. This has made it a potential over the counter substitute for self‐treating opioid withdrawal symptoms and achieving euphoric effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here